journal cover

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

The Lancet Oncology

Apr 10, 2018

John M WrangleMark P Rubinstein

Abstract

Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do initially respond then develop resistance to treatment. Agonists that target the shared interleukin-2 (IL-2) and IL-...read more

Mentioned in this Paper

Study
Monoclonal Antibodies
United States Food and Drug Administration
Monoclonal antibodies, antineoplastic
Biochemical Pathway
Treatment Protocols
Scientific Study
TNM Staging System
Academic Medical Centers
Lung
54
19
2
137
1
Paper Details
References
  • References
  • Citations9
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations9
1

Similar Papers Found In These Feeds

Drug & Digital Interventions

This feed describes how digital interventions, which are digital and mobile technologies used to support health system needs, can complement and improve pharmacotherapy in disease management. Discover the latest research on drug and digtial intervention here,

Influenza

Influenza, commonly known as the flu, is an infectious disease caused by an influenza virus.Symptoms can be mild to severe. The most common symptoms include: high fever, runny nose, sore throat, muscle pains, headache, coughing, sneezing, and feeling tired. Discover the latest research on influenza here.

Influenza Virus

Influenza viruses comprise a major class of human respiratory pathogens, responsible for causing morbidity and mortality worldwide. Discover the latest research on Influenza Viruses here.

American Thoracic Society: Clinical Problems

This feed has been developed in conjunction with the American Thoracic Society for the benefit of its Clinical Problems Assembly. It highlights new and impactful papers on clinical therapeutics, diagnoses, and practices pertaining to respiratory disease.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Viral Respiratory Diseases

Viral respiratory infections can affect the upper or lower respiratory tract. These lung and airway infections can be caused by numerous different viruses and can be dangerous for those who have a weakened immune system. Discover the latest research on viral respiratory diseases here.

Immunomodulating Agents

Immunomodulating agents are substances that stimulate or suppresse the immune system and may help the body combat againsts cancer, infection, or other diseases. Discover the latest research on immunomodulating agents here.

Immuno-Oncology

Immuno-oncology (or cancer immunotherapy) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules. Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. Discover the latest research on immuno-oncology here.

Lymphopenia

Lymphopenia has been associated with autoimmune pathology and it has been suggested that lymphopenia-induced proliferation of naive T cells may be responsible for the development of immune pathology. Here is the latest research.


© 2020 Meta ULC. All rights reserved

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

The Lancet Oncology

Apr 10, 2018

John M WrangleMark P Rubinstein

PMID: 29628312

DOI: 10.1016/s1470-2045(18)30148-7

Abstract

Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do initially respond then develop resistance to treatment. Agonists that target the shared interleukin-2 (IL-2) and IL-...read more

Mentioned in this Paper

Study
Monoclonal Antibodies
United States Food and Drug Administration
Monoclonal antibodies, antineoplastic
Biochemical Pathway
Treatment Protocols
Scientific Study
TNM Staging System
Academic Medical Centers
Lung
54
19
2
137
1

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References
  • Citations9
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations9
1
/papers/alt-803-an-il-15-superagonist-in-combination-with/29628312